Dubai: Bayer announced today the launch of its awareness campaign, ‘Building Bridges to Heart Health’, to urge the community to adopt preventive measures against cardiovascular diseases (CVD) across the UAE.
The campaign will include a series of screening events, the launch of innovative and artificial intelligence powered diagnostics solutions, as well as medical education to promote better heart health.
Mohamed Galal, Vice President and Head of Bayer Middle East Consumer Health said, “We have a commitment to increase knowledge and awareness around one of the most common causes of mortalities, CVDs. Through the campaign, our underlying objective is to build bridges between healthcare professionals, consumers, caregivers, as well as policy makers amongst others. We will also partner with leading heart and cardiology associations in the region to spread more awareness amongst patients and those at risk of CVDs.”
CVD death rates are on the rise across the UAE, Kuwait, Egypt, and Lebanon, and account for around 38%, 46%, 40%, 47% of total deaths respectively.[1]
Aspirin acts as a blood “thinner” and helps prevent blood clots from forming and helps prevent heart attack and stroke.[2]
In addition, Dr. Ahmed El Sokary, Consultant Intervention Cardiology at the Saudi German Hospital also said, “More people die annually from CVDs than from any cause. We must focus on altering our diets, engage in physical inactivity, stop tobacco and alcohol use, as they are all major risk factors of CVDs. [3] Such campaigns are an integral aspect of reducing the prevalence of CVDs. In the UAE, urgent commitment to CVD prevention from healthcare professionals, policymakers, government and other stakeholders and the promotion of healthy lifestyles, is warranted.”[4]
Prevention has been a longstanding objective of national governments throughout the region to combat the rising trend of cardiovascular diseases. Sponsored awareness campaigns, educational material as well as driving robust nutrition programs have been part of the equation. It is important to understand the underlying elements that help prevention of cardiovascular events.
“Our goal is to build a better, healthier future for people in the region. This will be achieved by the collective efforts in creating a sense of urgency and awareness around CVDs as well as its implications. We have a growing heart disease problem, and our work will help allow individuals to change their behaviors and improve their lives,” noted Galal.
– ENDS–
Bayer Middle East FZE
Dubai Internet City - Office Park Building
Block B, 5th Floor - P.O.Box: 500829 Dubai, UAE
Phone: + 971 4 4452700
Fax: + 971 4 4413247
Web: http://www.bayer.com
For Medical Information: med-info.me@bayer.com
For Safety Reporting: pv.me@bayer.com
Emeel Bishay
Director
FleishmanHillard
Emeel.Bishay@fleishman.com
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.com.
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
